Phase B-STYPE
I I-STYPE
/ I-STYPE
II I-STYPE
Clinical I-STYPE
Trial I-STYPE
- I-STYPE
Based I-STYPE
Early I-STYPE
Economic I-STYPE
Evaluation I-STYPE
of O
Acalabrutinib O
for O
Relapsed O
Chronic O
Lymphocytic O
Leukaemia O
Phase B-STYPE
I I-STYPE
/ I-STYPE
II I-STYPE
Clinical I-STYPE
Trial I-STYPE
- I-STYPE
Based I-STYPE
Early I-STYPE
Economic I-STYPE
Evaluation I-STYPE
of O
Acalabrutinib O
for O
Relapsed O
Chronic O
Lymphocytic O
Leukaemia O
18 O
July O
2019 O
18 O
July O
2019 O
RickAVreman B-AUTH

0000 O
- O
0002 O
- O
2076 O
- O
322X O
RickAVreman B-AUTH
Rick I-AUTH
A I-AUTH
Vreman I-AUTH
r.a.vreman@uu.nl O
0000 O
- O
0002 O
- O
2076 O
- O
322X O
JoostWGeenen B-AUTH
JoostWGeenen I-AUTH
Joost I-AUTH
W I-AUTH
Geenen I-AUTH
AnkeMHövels I-AUTH
AnkeMHövels I-AUTH
Anke I-AUTH
M I-AUTH
Hövels I-AUTH
WimGGoettsch I-AUTH

w.g.goettsch@uu.nl O
WimGGoettsch B-AUTH
Wim I-AUTH
G I-AUTH
Goettsch I-AUTH
w.g.goettsch@uu.nl O
HubertG B-AUTH
MLeufkens I-AUTH
HubertG I-AUTH
MLeufkens I-AUTH
Hubert I-AUTH
G I-AUTH
M I-AUTH
Leufkens I-AUTH
•Maiwenn I-AUTH
•Maiwenn I-AUTH
• O
Maiwenn B-AUTH
JAl I-AUTH
JAl O
J O
Al O
1 O
Division O
of O
Pharmacoepidemiology O
and O
Clinical O
Pharmacology O
, O
Utrecht O
Institute O
for O
Pharmaceutical O
Sciences O
, O
Utrecht O
University O
, O

Universiteitsweg O
99 O
, O
3584 O
CG O
Utrecht O
, O
The O
Netherlands O
Diemen O
, O
The O
Netherlands O
Rotterdam O
, O
The O
Netherlands O
1 O
Division O
of O
Pharmacoepidemiology O
and O
Clinical O
Pharmacology O
, O
Utrecht O
Institute O
for O
Pharmaceutical O
Sciences O
, O
Utrecht O
University O
, O

Universiteitsweg O
99 O
, O
3584 O
CG O
Utrecht O
, O
The O
Netherlands O
Diemen O
, O
The O
Netherlands O
Rotterdam O
, O
The O
Netherlands O
1 O
Division O
of O
Pharmacoepidemiology O
and O
Clinical O
Pharmacology O
, O
Utrecht O
Institute O
for O
Pharmaceutical O
Sciences O
, O
Utrecht O
University O
, O
Universiteitsweg O
99 O
, O
3584 O
CG O
Utrecht O
, O
The O
Netherlands O
Diemen O
, O
The O
Netherlands O
Rotterdam O
, O
The O
Netherlands O
Universiteitsweg O
99 O
, O
3584 O
CG O
Utrecht O
, O
The O
Netherlands O
Diemen O
, O
The O
Netherlands O
Rotterdam O
, O
The O
Netherlands O
2 O
The O
National O
Health O
Care O
Institute O
( O
ZIN O
) O
, O
2 O
The O
National O
Health O
Care O
Institute O
( O
ZIN O
) O
, O
2 O
The O
National O
Health O
Care O
Institute O
( O
ZIN O
) O
, O
3 O
Erasmus O
School O
of O
Health O
Policy O
and O
Management O
, O
Erasmus O
University O
Rotterdam O
, O
3 O
Erasmus O
School O
of O
Health O
Policy O
and O
Management O
, O
Erasmus O
University O
Rotterdam O
, O
3 O
Erasmus O
School O
of O
Health O
Policy O
and O
Management O
, O
Erasmus O
University O
Rotterdam O
, O
Phase B-STYPE
I I-STYPE
/ I-STYPE
II I-STYPE
Clinical I-STYPE
Trial I-STYPE
- I-STYPE
Based I-STYPE
Early I-STYPE
Economic I-STYPE
Evaluation I-STYPE
of O
Acalabrutinib O
for O
Relapsed O
Chronic O
Lymphocytic O
Leukaemia O
18 O
July O
2019 O
18 O
July O
2019 O
18 O
July O
2019 O
10.1007 O
/ O
s40258 O
- O
019 O
- O
00496 O
- O
1 O

Bruton O
's O
tyrosine O
kinase O
( O
BTK O
) O
inhibitors O
represent O
a O
new O
line O
of O
treatment O
for O
chronic O
lymphocytic O
leukaemia O
( O
CLL O
) O
, O
with O
drugs O
in O
development O
and O
one O
already O
on O
the O
market O
: O
ibrutinib O
. O
Ibrutinib O
has O
now O
been O
approved O
for O
previously O
treated O
and O
untreated O
CLL O
and O
has O
been O
shown O
to O
be O
clinically O
effective O
with O
a O
durable O
response O
[ O
1][2][3 O
] O
. O
However O
, O
ibrutinib O
is O
not O
entirely O
specific O
for O
BTK O
. O
It O
may O
also O
inhibit O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
, O
interleukin-2-inducible O
T O
cell O
kinase O
( O
ITK O
) O
, O
T O
- O
cell O
X O
chromosome O
kinase O
, O
and O
tyrosine O
kinase O
expressed O
in O
hepatocellular O
carcinoma O
( O
TEC O
) O
family O
proteins O
, O
leading O
to O
side O
effects O
such O
as O
bleeding O
, O
atrial O
fibrillation O
, O
rash O
and O
diarrhoea O
[ O
4][5][6 O
] O
. O

Based O
on O
this O
model O
, O
even O
with O
a O
price O
equal O
to O
ibrutinib O
, O
acalabrutinib O
is O
not O
cost O
effective O
with O
a O
willingness O
- O
topay O
threshold O
of O
£ O
50,000 O
. O
The O
probability O
of O
acalabrutinib O
being O
cost O
effective O
declines O
with O
greater O
efficacy O
. O

Cost B-STYPE
- I-STYPE
effectiveness I-STYPE
analyses I-STYPE
for O
acalabrutinib O
lead O
to O
incentives O
to O
show O
a O
lack O
of O
progression B-METRIC
- I-METRIC
free I-METRIC
survival I-METRIC
benefit O
because O
the O
additional O
costs O
associated O
with O
prolonged O
progression B-METRIC
- I-METRIC
free I-METRIC
survival I-METRIC
are O
not O
offset O
by O
the O
additional O
quality O
- O
adjusted O
life O
- O
years O
gained O
. O

The O
conflicting O
effects O
of O
quality O
of O
life O
and O
survival O
benefits O
disrupt O
proper O
assessment O
of O
the O
added O
value O
of O
acalabrutinib O
, O
which O
might O
lead O
to O
delays O
in O
patient O
access O
. O

To O
get O
novel O
haematological O
agents O
to O
patients O
effectively O
and O
in O
a O
timely O
manner O
, O
development O
should O
include O
an O
early O
assessment O
of O
added O
value O
such O
as O
that O
presented O
here O
. O
makers O
and O
manufacturers O
to O
streamline O
clinical O
development O
and O
reimbursement O
processes O
[ O
15][16][17][18 O
] O
. O

The O
objective O
of O
this O
study O
was O
to O
construct O
, O
based O
on O
published O
phase B-STYPE
I I-STYPE
/ I-STYPE
II I-STYPE
data I-STYPE
, I-STYPE
an I-STYPE
early I-STYPE
cost I-STYPE
- I-STYPE
utility I-STYPE
analysis I-STYPE
comparing O
acalabrutinib B-DESC
and O
ibrutinib B-DESC
for O
chronic O
lymphocytic O
leukaemia O
to O
assist O
early O
reimbursement O
decision O
making O
. O
Sensitivity O
analyses O
were O
performed O
, O
and O
possible O
development O
scenarios O
were O
assessed O
, O
identifying O
critical O
parameters O
and O
quantifying O
their O
relative O
impact O
on O
incremental O
costs O
and O
QALYs O
. O

An O
effectively O
lifetime O
partitioned O
survival O
model O
comparing O
acalabrutinib O
and O
ibrutinib B-DESC
was O
constructed O
in O
Microsoft O
Excel O
( O
Microsoft O
, O
Redmond O
, O
WA O
, O
USA O
) O
from O
a O
UK O
national O
health O
service O
perspective O
. O
As O
portrayed O
in O
Fig O
. O
1 O
, O
included O
health O
states O
were O
progression B-METRIC
- I-METRIC
free I-METRIC
survival I-METRIC
( O
PFS B-METRIC
) O
, O
post O
- O
progression O
survival O
( O
PPS O
) O
and O
death O
. O
PPS O
was O
split O
into O
two O
sub O
- O
states O
: O
subsequent O
treatment O
( O
PPS O
- O
ST O
) O
and O
best O
supportive O
care O
( O
PPS O
- O
BSC O
) O
. O
The O
modelled B-STYPE
population I-STYPE
was O
based O
on O
the O
only O
available O
phase B-STYPE
I I-STYPE
/ I-STYPE
II I-STYPE
trial I-STYPE
for O
acalabrutinib B-DESC
and O
assumed O
representative O
for O
the O
UK O
relapsed O
CLL O
patient O
population O
[ O
13 O
] O
. O
The O
model O
was O
based O
on O
the O
NICE O
assessment O
of O
the O
manufacturer O
's O
submission O
for O
ibrutinib O
, O
appraisal O
number O
TA429 O
[ O
14 O
] O
. O
Patients O
moved O
between O
health O
states O
in O
cycles O
of O
28 O
days O
with O
a O
time O
horizon O
of O
30 O
years O
( O
effectively O
lifetime O
) O
. O
Half O
- O
cycle O
corrections O
were O
applied O
. O
Costs O
and O
outcomes O
were O
both O
discounted O
by O
3.5 O
% O
. O
The O
model O
was O
constructed O
according O
to O
International O
Society O
for O
Pharmacoeconomics O
and O
Outcomes O
Research O
good O
modelling O
practice O
, O
and O
method O
reporting O
follows O
the O
In O
preclinical O
research O
, O
acalabrutinib B-DESC
did O
not O
inhibit O
EGFR O
, O
TEC O
, O
ITK O
or O
other O
agents O
[ O
7][8][9][10 O
] O
. O
Like O
ibrutinib B-DESC
, O
acalabrutinib B-DESC
binds O
covalently O
to O
Cys481 O
in O
the O
adenosine O
triphosphate O
( O
ATP O
) O
binding O
pocket O
of O
BTK O
. O
It O
shows O
a O
rapid O
oral O
absorption O
with O
a O
short O
plasma O
half O
- O
life O
, O
theoretically O
leading O
to O
less O
toxicity O
[ O
11,12 O
] O
. O
Early O
clinical O
studies O
with O
acalabrutinib B-DESC
showed O
overall O
response O
rates O
of O
95 O
% O
at O
median O
followup O
of O
14.3 O
months O
and O
mostly O
grade O
1 O
or O
2 O
adverse O
events O
without O
dose O
- O
limiting O
toxicity O
[ O
13 O
] O
. O

Based O
on O
these O
findings O
, O
acalabrutinib B-DESC
would O
be O
a O
valuable O
addition O
to O
the O
therapeutic O
options O
for O
CLL O
. O
However O
, O
patient O
access O
also O
relies O
on O
the O
decisions O
of O
health O
technology O
assessment O
( O
HTA O
) O
bodies O
. O
In O
the O
UK O
, O
the O
National O
Institute O
for O
Health O
and O
Care O
Excellence O
( O
NICE O
) O
reported O
that O
ibrutinib B-DESC
's O
initial O
price O
led O
to O
a O
base O
- O
case O
incremental O
costeffectiveness O
ratio O
( O
ICER O
) O
of O
£ O
45,486 O
per O
quality O
- O
adjusted O
life O
- O
year O
( O
QALY O
) O
when O
compared O
with O
treatment O
with O
physicians O
' O
choice O
[ O
14 O
] O
. O
They O
advised O
to O
reimburse O
ibrutinib B-DESC
only O
if O
the O
negotiated O
( O
confidential O
) O
discount O
would O
be O
upheld O
. O
Such O
evaluations O
by O
HTA O
bodies O
and O
concomitant O
price O
negotiations O
can O
take O
up O
to O
a O
year O
, O
delaying O
patient O
access O
. O

To O
reduce O
delays O
in O
patient O
access O
, O
it O
is O
possible O
to O
start O
early O
with O
the O
assessment O
of O
added O
value O
of O
a O
new O
therapy O
. O
This O
can O
start O
during O
preclinical O
development O
but O
is O
more O
regularly O
executed O
during O
phase O
I O
or O
II O
clinical O
trials O
. O
One O
method O
is O
the O
use O
of O
early O
cost O
- O
utility O
analyses O
, O
which O
can O
clarify O
the O
relative O
impact O
of O
the O
parameters O
that O
drive O
cost O
effectiveness O
. O
Early O
cost O
- O
utility O
analyses O
allow O
decision O
Consolidated O
Health O
Economic O
Evaluation O
Reporting O
Standards O
statement O
for O
reporting O
standards O
[ O
19 O
] O
. O

Ibrutinib B-DESC
420 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
day I-DOSAGE
( I-DOSAGE
three I-DOSAGE
capsules I-DOSAGE
) I-DOSAGE
is I-DOSAGE
administered I-DOSAGE
until I-DOSAGE
disease I-DOSAGE
progression I-DOSAGE
or I-DOSAGE
until I-DOSAGE
no I-DOSAGE
longer I-DOSAGE
tolerated I-DOSAGE
by I-DOSAGE
the I-DOSAGE
patient I-DOSAGE
. O
Acalabrutinib B-DESC
is O
given O
as O
200 B-DOSAGE
mg I-DOSAGE
/ I-DOSAGE
day I-DOSAGE
( I-DOSAGE
two I-DOSAGE
capsules I-DOSAGE
) I-DOSAGE
. O
After O
progression O
, O
41.9 O
% O
of O
patients O
receive O
subsequent O
treatment O
. O
Subsequent O
treatment O
consists O
of O
rituximab O
and O
idelalisib O
. O
Rituximab O
is O
given O
in O
six O
cycles O
of O
4 O
weeks O
, O
with O
an O
initial O
dose O
of O
375 O
mg O
/ O
m O
2 O
and O
subsequent O
doses O
of O
500 O
mg O
/ O
m O
2 O
, O
according O
to O
the O
NICE O
guideline O
for O
CLL O
[ O
20 O
] O
. O
Idelalisib O
is O
administered O
until O
disease O
progression O
or O
death O
in O
a O
dose O
of O
150 O
mg O
twice O
daily O
. O
A O
dose O
intensity O
of O
94.8 O
% O
was O
applied O
for O
acalabrutinib B-DESC
, O
ibrutinib O
and O
idelalisib O
, O
in O
accordance O
with O
findings O
from O
the O
RESONATE O
trial O
[ O
2,14 O
] O
. O
In O
this O
study O
, O
acalabrutinib B-DESC
was O
assessed O
relative O
only O
to O
its O
primary O
comparator O
from O
the O
same O
class O
within O
the O
same O
indication O
( O
ibrutinib O
) O
, O
as O
this O
is O
expected O
to O
be O
the O
main O
competitor O
in O
practice O
. O
Ofatumumab O
, O
physician O
's O
choice O
or O
other O
treatment O
regimens O
were O
not O
assessed O
in O
this O
study O
. O
[ O
13 O
] O
. O
PFS B-METRIC
and O
OS O
individual O
patient O
data O
for O
ibrutinib B-DESC
was O
reconstructed O
from O
the O
reported O
Kaplan O
- O
Meier O
curves O
[ O
21 O
] O
. O

PPS O
is O
defined O
as O
OS O
minus O
PFS B-METRIC
and O
comprises O
patients O
receiving O
subsequent O
treatment O
as O
well O
as O
patients O
receiving O
best O
supportive O
care O
. O
PPS O
- O
ST O
was O
implemented O
by O
plotting O
a O
Weibull O
curve O
from O
the O
PFS B-METRIC
given O
in O
the O
Kaplan O
- O
Meier O
graph O
provided O
by O
Furman O
et O
al O
. O
[ O
22 O
] O
. O
The O
Weibull O
curve O
was O
chosen O
because O
NICE O
evaluated O
it O
as O
being O
the O
most O
suited O
curve O
for O
this O
treatment O
. O
In O
this O
multicentre O
, O
randomised O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
phase O
III O
study O
, O
the O
efficacy O
of O
rituximab O
and O
idelalisib O
combination O
therapy O
was O
assessed O
in O
patients O
with O
relapsed O
CLL O
[ O
22 O
] O
. O
After O
80 O
cycles O
( O
75 O
months O
) O
, O
Weibull O
plotted O
survival O
was O
< O
0.01 O
% O
and O
therefore O
assumed O
to O
be O
0 O
. O
Because O
transition O
probabilities O
to O
the O
PPS O
state O
are O
not O
explicitly O
modelled O
in O
a O
partitioned O
survival O
model O
, O
entry O
into O
the O
PPS O
state O
each O
cycle O
was O
calculated O
by O
subtracting O
a O
specific O
background O
mortality O
from O
the O
proportion O
of O
patients O
leaving O
PFS B-METRIC
. O
This O
background O
mortality O
was O
retrieved O
from O
the O
Life O
Expectancy O
Tables O
from O
the O
Office O
for O
National O
Statistics O
[ O
23 O
] O
. O
This O
method O
was O
also O
used O
in O
the O
ibrutinib O
submission O
; O
however O
, O
the O
background O
mortality O
was O
considered O
fixed O
, O
whereas O
ours O
increased O
with O
increasing O
age O
. O

Unit O
costs O
for O
the O
drug O
treatments O
were O
provided O
by O
the O
British O
National O
Formulary O
[ O
24 O
] O
. O
All O
costs O
are O
reported O
in O
UK O
pound O
sterling O
( O
£ O
) O
, O
year O
2018 O
values O
. O
When O
cost O
inputs O
were O
based O
on O
different O
years O
, O
they O
were O
inflated O
with O
the O
Hospital O
and O
Community O
Health O
Services O
Pay O
and O
Price O
Index O
and O
, O
after O
discontinuation O
of O
this O
index O
in O
2017 O
, O
with O
the O
healthspecific O
subset O
of O
the O
consumer O
price O
inflation O
index O
[ O
25 O
] O
. O
Daily O
costs O
for O
acalabrutinib B-DESC
treatment O
were O
assumed O
equal O
to O
ibrutinib B-DESC
in O
the O
base O
- O
case O
and O
sensitivity O
analyses O
and O
varied O
through O
scenario O
analyses O
, O
testing O
for O
30 O
% O
pricing O
premiums O
and O
reductions O
( O
Table O
1 O
) O
. O
Costs O
for O
rituximab O
are O
only O
inflicted O
in O
the O
first O
six O
cycles O
of O
subsequent O
treatment O
, O
in O
accordance O
with O
its O
approved O
indication O
, O
and O
are O
based O
on O
an O
average O
body O
surface O
area O
of O
1.9 O
m O
2 O
[ O
14 O
] O
. O
Full O
calculations O
for O
costs O
per O
cycle O
of O
treatment O
with O
acalabrutinib B-DESC
, O
ibrutinib B-DESC
and O
rituximab O
+ O
idelalisib O
are O
provided O
in O
ESM O
2 O
. O

Costs O
of O
grade O
3 O
and O
4 O
adverse O
events O
( O
AEs O
) O
were O
included O
according O
to O
the O
UK O
national O
schedule O
of O
reference O
costs O
2015 O
- O
2016 O
[ O
26 O
] O
. O
Incidences O
were O
implemented O
from O
clinical O
trials O
for O
acalabrutinib B-DESC
and O
from O
the O
NICE O
ibrutinib B-DESC
assessment O
[ O
13,14 O
] O
. O
AE O
costs O
were O
inflicted O
once O
, O
in O
the O
first O
cycle O
. O
This O
matched O
the O
approach O
used O
in O
the O
NICE O
ibrutinib B-DESC
submission O
and O
is O
supported O
by O
the O
fact O
that O
onset O
of O
side O
effects O
was O
generally O
within O
the O
first O
half O
year O
and O
the O
duration O
of O
side O
effects O
was O
short O
[ O
2,14 O
] O
. O

Annual O
healthcare O
resource O
use O
such O
as O
hospital O
visits O
or O
blood O
tests O
associated O
with O
routine O
follow O
- O
up O
care O
was O
included O
. O
Resource O
use O
is O
based O
on O
expert O
elicitation O
reported O
by O
the O
manufacturer O
in O
the O
ibrutinib B-DESC
submission O
and O
differs O
per O
model O
state O
( O
PFS B-METRIC
, O
PPS O
- O
ST O
, O
PPS O
- O
BSC O
) O
and O
whether O
the O
patient O
in O
the O
PFS B-METRIC
state O
was O
a O
complete O
responder O
( O
CR O
) O
, O
partial O
responder O
( O
PR O
) O
or O
non O
- O
responder O
( O
NR O
, O
including O
stable O
disease O
and O
progressive O
disease O
) O
. O
Treatment O
responses O
for O
ibrutinib B-DESC
were O
reported O
to O
be O
84 O
% O
PR O
, O
6 O
% O
CR O
and O
10 O
% O
NR O
. O
For O
acalabrutinib B-DESC
, O
95 O
% O
were O
PR O
and O
5 O
% O
were O
NR O
[ O
13,14 O
] O
. O
Full O
calculations O
of O
AE O
costs O
and O
resource O
use O
per O
treatment O
are O
provided O
in O
ESM O
3 O
. O

Costs O
for O
the O
death O
state O
were O
inflicted O
once O
in O
the O
cycle O
when O
death O
happened O
and O
equal O
the O
per O
patient O
costs O
of O
healthcare O
utilisation O
during O
the O
last O
30 O
days O
of O
life O
for O
patients O
aged O
≥ O
65 O
years O
with O
any O
cancer O
reported O
by O
Bekelman O
et O
al O
. O
[ O
27 O
] O
. O
Costs O
and O
ranges O
for O
sensitivity O
analyses O
are O
stated O
in O
Table O
1 O
. O